ABSTRACT
Dendritic cells (DCs), the most potent antigen-presenting cells (APCs), were discovered almost 30 years ago. Due to the priming of antigen-specific immune responses mediated by CD4+ and CD8+ lymphocytes, DCs are crucial for the induction of adaptive immunity against cancer. Therefore, vaccination of cancer patients with DCs presenting tumour-associated antigens (TAAs) have been believed to be a promising anticancer strategy. Multiple clinical trials have been carried out in order to evaluate the safety and efficacy of cancer vaccines based on antigen-pulsed DCs. However, pulsing of DCs with particular peptides has several disadvantages: i) short-time duration of antigen-major histocompatability complex (MHC) complexes, ii) a requirement for matching defined peptides with MHC complexes and iii) exclusive presentation of single antigen epitopes. Application of gene transfer technologies in the field of DC-based vaccines made possible the development of novel, anticancer immunisation strategies. In several animal models, DCs modified with genes encoding TAA or immunostimulatory proteins have been shown to be effective in the induction of antitumour immune responses. Based on these encouraging results, a first clinical trial of prostate cancer patients vaccinated with gene modified DCs has recently been initiated. In this article, methods used for genetic modification of DCs and anticancer vaccination strategies based on genetically modified DCs are reviewed.
Subject(s)
Dendritic Cells/physiology , Dendritic Cells/transplantation , Neoplasms/therapy , Animals , Genetic Therapy , HumansABSTRACT
A method was developed to compare the lymphocytic infiltrates in regressing vs. progressing experimental mouse tumors using a model for human papillomavirus-16 (HPV-16) oncoprotein-linked cancer. Tumor cells mixed with matrigel, composed of natural matrix substances that provide a basement membrane structure for adherent cells, were inoculated into mice vaccinated with an efficacious vaccine to the E7 oncoprotein or a vaccine to a control antigen. The tumor cells remained within the solidified gel and recruited a cellular infiltrate that could readily be analyzed upon removal of the gelatinous mass containing progressing or regressing tumors. The results show that tumors recruit activated CD8(+) T cells regardless of their antigen specificity. In regressing tumors expressing an appropriate target antigen for the vaccine-induced CD8(+) T cells, a strong increase of the tumor antigen-specific T cell population was observed over time. Progressing tumors that lacked the target antigen for the activated CD8(+) T cell population did not show this selective enrichment.
Subject(s)
CD8-Positive T-Lymphocytes/immunology , Collagen , Drug Combinations , Laminin , Lymphocytes, Tumor-Infiltrating/immunology , Neoplasms, Experimental/immunology , Papillomavirus Infections/immunology , Proteoglycans , Tumor Virus Infections/immunology , Animals , Antigens, Viral, Tumor/immunology , Cancer Vaccines , Chemokines/biosynthesis , Chemokines/genetics , Cytotoxicity Tests, Immunologic , Female , Lymphocyte Activation , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Neoplasms, Experimental/therapy , Oncogene Proteins, Viral/immunology , Papillomavirus E7 Proteins , Papillomavirus Infections/therapy , Tumor Cells, Cultured , Tumor Virus Infections/therapy , Viral VaccinesABSTRACT
Protection to sexually transmitted infections with oncogenic human papillomaviruses (HPV) such as type 16 is thought to be provided by neutralizing antibodies directed to the major outer capsid protein, the L1 protein. A DNA vaccine and an E1-deleted adenoviral recombinant human strain 5, both expressing the L1 protein of HPV-16, were developed and shown to express L1 protein able to assemble into virus-like particles (VLPs). The vaccines used in a prime-boost regimen, with the DNA given intramuscularly (i.m.) for priming, followed by an intranasal (i.n.) booster immunization with the viral recombinant, induced antibodies to L1 in sera and in vaginal secretions.
Subject(s)
Capsid Proteins , Papillomaviridae/immunology , Papillomavirus Infections/immunology , Papillomavirus Infections/prevention & control , Tumor Virus Infections/immunology , Tumor Virus Infections/prevention & control , Administration, Intranasal , Animals , Antibodies, Viral/biosynthesis , Antigens, Viral/chemistry , Antigens, Viral/genetics , COS Cells , Cell Line , Epitopes/chemistry , Epitopes/genetics , Female , Humans , Immunization, Secondary , Injections, Intramuscular , Mice , Mice, Inbred C57BL , Microscopy, Electron , Oncogene Proteins, Viral/genetics , Oncogene Proteins, Viral/immunology , Papillomaviridae/genetics , Papillomaviridae/pathogenicity , Papillomaviridae/ultrastructure , Papillomavirus Vaccines , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/genetics , Viral Vaccines/administration & dosage , Viral Vaccines/geneticsSubject(s)
Cancer Vaccines/therapeutic use , Carcinoma, Renal Cell/therapy , Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Interleukin-6/therapeutic use , Kidney Neoplasms/therapy , Animals , Cancer Vaccines/genetics , Carcinoma, Renal Cell/immunology , Carcinoma, Renal Cell/pathology , Genetic Therapy , Granulocyte-Macrophage Colony-Stimulating Factor/genetics , Interleukin-6/genetics , Kidney Neoplasms/immunology , Kidney Neoplasms/pathology , Lymphocytes, Tumor-Infiltrating/immunology , Mice , Mice, Inbred BALB C , Tumor Cells, CulturedABSTRACT
Defining immune responses against the secreted transgene product in a gene therapy setting is critical for treatment of genetic diseases such as hemophilia B (coagulation factor IX deficiency). We have previously shown that intramuscular administration of an adeno-associated viral (AAV) vector results in stable expression of therapeutic levels of factor IX (F.IX) and may be associated with humoral immune responses against F.IX. This study demonstrates that intramuscular injection of an AAV vector expressing F.IX fails to activate F.IX-specific cytotoxic T lymphocytes (CTLs) in hemostatically normal or in hemophilia B mice, so that there is an absence of cellular immune responses against F.IX. However, transgene-derived F.IX can cause B cell responses characterized by production of T helper cell-dependent antibodies (predominantly IgG1, but also IgG2 subclasses) resulting from activation of CD4+ T helper cells primarily of the Th2 subset. In contrast, administration of an adenoviral vector efficiently activated F.IX-specific CTLs and T helper cells of both Th1 and Th2 subsets, leading to inflammation and destruction of transduced muscle tissue and activation of B cells as well. Therefore, vector sequences fundamentally influence T cell responses against transgene-encoded F.IX. In conclusion, activation of the immune system in AAV-mediated gene transfer is restricted to pathways mediated by F.IX antigen presentation through MHC class II determinants resulting in T and B cell responses that are more comparable to responses in the setting of protein infusion rather than of viral infection/gene transfer.
Subject(s)
Factor IX/metabolism , Gene Transfer Techniques/adverse effects , Genetic Vectors/immunology , T-Lymphocyte Subsets/immunology , Transgenes , Adenoviridae/genetics , Adoptive Transfer , Animals , Cytokines/metabolism , Factor IX/genetics , Factor IX/immunology , Fluorescent Antibody Technique , Hemophilia B/immunology , Hemophilia B/metabolism , Immunoglobulin G/biosynthesis , Immunoglobulin G/immunology , Mice , Mice, Inbred C57BL , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/metabolism , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/metabolism , Th1 Cells/immunology , Th1 Cells/metabolism , Th2 Cells/immunology , Th2 Cells/metabolismABSTRACT
A novel method for quantitative analysis of tumor-specific CD8(+) T lymphocytes was developed. Lymphocytes from mice vaccinated with tumor-associated antigens (TAAs) were expanded for 5 days in tissue culture and then stimulated in vitro for 5 h with tumor cells. They were subsequently surface-stained for CD8 and for intracellular interferon gamma (IFN-gamma) and analyzed by flow cytometry. The specificity and sensitivity of this assay, staining of antigen-activated lymphocytes (SAAL), was comparable to that of surface staining with major histocompatibily class (MHC) I-peptide tetramers or of staining of peptide re-stimulated CD8(+) T cells for intracellular IFN-gamma. The assay did not exhibit the high background activity of traditional 51Cr-release assays that without elaborate effector cell purifications commonly fail to distinguish between T cell-mediated antigen-specific cytolysis and non-specific lysis by lymphokine-activated killer (LAK) cells. The described method, which does not require prior identification of individual TAAs and their T cell epitopes nor access to specific reagents such as MHC-peptide tetramers, represents a simple yet useful technique for studying tumor-specific cytolytic T cell responses.
Subject(s)
Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Flow Cytometry/methods , Lymphocyte Activation , T-Lymphocytes, Cytotoxic/immunology , Animals , Chromium Radioisotopes , Cytotoxicity Tests, Immunologic , Mice , Staining and Labeling/methodsABSTRACT
Most cancerous lesions of the uterine cervix are linked to persistent infections with human papillomaviruses (HPV), most notably HPV-16 or -18. Vaccine-induced immune responses to the HPV early antigens E6 and E7, which contribute to cell transformation and are thus expressed in these cervical cancers, could potentially eradicate malignant cells. We generated recombinant vaccines based on E1-deleted adenovirus human strain 5 or on vaccinia virus strain Copenhagen expressing either the E6 or E7 oncoproteins of HPV-16. The different vaccines were compared in two experimental mouse tumor models employing Balb/c or C57Bl/6 mice. Data presented here demonstrate that depending on the model either CD4(+) or CD8(+) T cells provide protection to tumor cell challenge, resulting in striking differences in the efficacy of the four vaccines under investigation.
Subject(s)
Antigens, Viral/immunology , Oncogene Proteins, Viral/immunology , Papillomaviridae/immunology , Papillomavirus Vaccines , Repressor Proteins , Vaccines, Synthetic/immunology , Viral Vaccines/immunology , Adenoviruses, Human/genetics , Animals , Female , Genetic Vectors/genetics , Interferon-gamma/genetics , Interferon-gamma/immunology , Lung Neoplasms/immunology , Lung Neoplasms/metabolism , Lung Neoplasms/prevention & control , Lung Neoplasms/secondary , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Neoplasm Transplantation , Papillomavirus E7 Proteins , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Cytotoxic/immunology , Tumor Cells, Cultured , Vaccinia virus/geneticsABSTRACT
DNA vaccines, based on plasmid vectors expressing an antigen under the control of a strong promoter, have been shown to induce protective immune responses to a number of pathogens, including viruses, bacteria and parasites. They have also displayed efficacy in treatment or prevention of cancer, allergic diseases and autoimmunity. Immunologically, DNA vaccines induce a full spectrum of immune responses that include cytolytic T cells, T helper cells and antibodies. The immune response to DNA vaccines can be enhanced by genetic engineering of the antigen to facilitate its presentation to B and T cells. Furthermore, the immune response can be modulated by genetic adjuvants in the form of vectors expressing biologically active determinants or by more traditional adjuvants that facilitate uptake of DNA into cells. The ease of genetic manipulation of DNA vaccines invites their use not only as vaccines but also as research tools for immunologists and microbiologists.